Prof. Kenneth McDonald

Prof. Kenneth McDonald is Ireland's most distinguished heart failure cardiologist, holding a consultant appointment at St Vincent's University Hospital in Dublin — one of Ireland's largest and most clinically advanced teaching hospitals — and a professorial appointment at University College Dublin (UCD). With over 28 years of dedicated clinical and research experience in heart failure and cardiomyopathy, he has established himself as one of Ireland's most important contributors to cardiovascular medicine.

St Vincent's University Hospital hosts the national advanced heart failure programme for Ireland, and Prof. McDonald leads the heart failure clinical service, which manages patients from across Ireland with complex and refractory heart failure, including those being evaluated for advanced therapies such as cardiac resynchronization therapy (CRT), implantable cardioverter-defibrillators (ICD), and cardiac transplantation workup.

Prof. McDonald is widely known in the international cardiology community for his research on natriuretic peptide-guided heart failure management — specifically the use of BNP (brain natriuretic peptide) and NT-proBNP as therapeutic targets to guide diuretic and neurohormonal therapy titration in patients with systolic heart failure. His participation in the GUIDE-IT trial — one of the largest randomised trials of biomarker-guided heart failure therapy — has contributed substantially to evidence-based management guidelines.

He is a board member of the ESC Heart Failure Association and has contributed to the development of ESC heart failure guidelines, representing the Republic of Ireland in European cardiovascular medicine governance. His clinical practice integrates device therapy, pharmacological optimisation, and structured heart failure clinic follow-up, providing patients with a comprehensive management programme that reduces hospitalisation and improves quality of life.

Prof. McDonald completed his undergraduate medical degree at University College Dublin (UCD) and subsequently trained in internal medicine and cardiology at St Vincent's University Hospital and affiliated Irish teaching hospitals. He pursued specialist training in heart failure and cardiac electrophysiology, developing expertise in both the pharmacological management of heart failure and the implantation and programming of cardiac devices — ICDs and CRT systems.

He completed research fellowship training in heart failure and biomarker science at leading centres in the United States and Europe, which underpinned his career as a clinical trialist in heart failure medicine. He holds the Fellowship of the Royal College of Physicians of Ireland (FRCPI) and the Fellowship of the European Society of Cardiology (FESC). His academic appointment at UCD allows him to combine clinical practice with teaching and research supervision.

Prof. McDonald's clinical practice encompasses the comprehensive management of heart failure across both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). He optimises neurohormonal therapy — including ACE inhibitors, ARNIs (sacubitril/valsartan), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — and uses natriuretic peptide monitoring (BNP and NT-proBNP) to guide titration decisions.

His device expertise includes implantable cardioverter-defibrillator (ICD) implantation for sudden cardiac death prevention and cardiac resynchronization therapy (CRT and CRT-D) for patients with dyssynchronous heart failure. He performs cardiac catheterisation for haemodynamic assessment and coronary evaluation in heart failure patients. Complex cardiomyopathies — including dilated, hypertrophic, and arrhythmogenic cardiomyopathies — are managed through St Vincent's multidisciplinary inherited cardiac conditions clinic.

Prof. McDonald has authored over 150 peer-reviewed publications in leading cardiovascular journals including the European Heart Journal, JACC Heart Failure, Circulation, and the American Heart Journal. His research on natriuretic peptide-guided therapy and the clinical utility of BNP and NT-proBNP in heart failure management has been widely cited and has informed ESC heart failure guidelines.

He contributed to the GUIDE-IT trial (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment) — a landmark multicentre randomised trial comparing NT-proBNP-guided therapy against usual care in patients with high-risk heart failure. He has also published extensively on the outcomes of cardiac resynchronization therapy and ICD therapy in Irish and European heart failure populations, as well as on quality-of-life outcomes and healthcare utilisation in chronic heart failure. He presents regularly at ESC Congress and the Heart Failure Association meeting.

St Vincent's University Hospital is Dublin's largest private and public teaching hospital and is well experienced in providing specialist cardiac services to Irish patients and to international visitors. Prof. McDonald consults exclusively in English. Video consultations are available for patients abroad seeking a second opinion on a heart failure diagnosis, device therapy recommendation, or cardiomyopathy assessment.

Ireland is a member of the EU, and EU/EEA patients can access specialist cardiology services under the European Health Insurance Card (EHIC) scheme or the cross-border healthcare directive. Dublin Airport is directly connected to airports across Europe, North America, and the Middle East, making St Vincent's accessible for international medical travel. The hospital's international patient office provides administrative support for non-Irish patients.

Prof. McDonald has been recognised by the Irish Cardiac Society (ICS) as a Distinguished Fellow for his sustained contributions to cardiology in Ireland. He serves on the board of the ESC Heart Failure Association — one of the most important scientific bodies in European cardiovascular medicine — contributing to heart failure guideline development and international clinical trial governance. He has been nominated to the Royal Irish Academy in recognition of his contributions to medical science. His sustained engagement with HFSA (Heart Failure Society of America) reflects the transatlantic reach of his scientific reputation.